Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4948-4955

  Xiang, Rong ^a   Lode, Holger N ^a   Dolman, Carrie S ^a   Dreier, Torsten ^a   Varki, Nissi M ^b   Qian, Xiuqi ^c   Lo, Kin Ming ^c   Lan, Yan ^c   Super, Michael ^c   Gillies, Stephen D ^c   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fuji ImmunoPharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 FUSION PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT HUMANIZED ANTIBODY INTERLEUKIN 2 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTOXINS; INTERLEUKIN-2; KILLER CELLS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, SCID; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED;

EID: 0030856116     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Steimle, S. Experts call for action to prevent colon cancer deaths by spurring screening awareness. J. Natl. Cancer Inst. (Bethesda), 97: 415-416, 1997.
2. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 94: 1177-1183, 1994.
3. Talmage, D. W., Woolnough, J. A., Hemmingsen, H., Lopez, L., and Lafferty, K. J. Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc. Natl. Acad. Sci. USA. 77: 4610-4614, 1977.
4. Rosenberg, S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. (Bethesda), 96: 1635-1644, 1996.
5. Forni, G., Giovarelli, M., Santoni, A., Modesti, A., and Forni, M. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivily. J. Immunol., 87: 4033-4041, 1987.
6. Ostrand-Rosenberg, S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol., 94: 722-727, 1994.
7. Schmidt-Wolf, G. D., and Schmidt-Wolf, I. G. Cytokines and gene therapy. Immunol. Today, 95: 173-175, 1995.
8. Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
9. Perez, M. S., and Walker, L. E. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J. Immunol., 89: 3662-3667, 1989.
10. Linnenbach, A. J., Seng, B. A., Wu, S., Robbins, S., Scollon, M., Pyrc, J. J., Druck, T., and Huebner, K. Retroposition in a family of carcinoma-associated antigen genes. Mol. Cell. Biol., 93: 1507-1515, 1993.
11. Varki, N. M., Reisfeld, R. A., and Walker, L. E. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res., 44: 681-687, 1984.
12. Mueller, B. M., Reisfeld, R. A., and Gillies, S. D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc. Natl. Acad. Sci. USA, 87: 5702-5705, 1990.
13. Gillies, S. D., Reilly, E. B., Lo, K. M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA, 89: 1428-1432, 1992.
14. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 90: 397-403, 1990.
15. Maass, G., Schmidt, W., Berger, M., Schilcher, F., Koszik, F., Schneeberger, A., Stingl, G., Birnstiel, M. L., and Schweighoffer, T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA, 95: 5540-5544, 1995.
16. Zatloukal, K., Schneeberger, A., Berger, M., Schmidt, W., Koszik, F., Kutil, R., Cotten, M., Wagner, E., Buschle, M., Maass, G., et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J. Immunol., 95: 3406-3419, 1995.
17. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 90: 1217-1224, 1990.
18. Sprent, J. Antigen-presenting cells. Professionals and amateurs. Curr. Biol., 95: 1095-1097, 1995.
19. + T cells. Immunol. Rev. 117: 213-234, 1990.
20. + T lymphocytes. J. Immunol., 151: 5993-6001, 1993.
21. Cai, Z., and Sprent, J. Resting and activated T cells display different requirements for CD8 molecules. J. Exp. Med., 179: 2005-2015, 1994.
22. Hahn, S., Gehri, R., and Erb, P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev., 146: 57-79, 1995.
23. Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M., and Jaffee, E. M. The immunodominant major histocompalibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA. 96: 9730-9735, 1996.